journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology

journal
https://read.qxmd.com/read/30985017/impact-of-2016-who-diagnosis-of-early-and-overt-primary-myelofibrosis-on-presentation-and-outcome-of-232-patients-treated-with-ruxolitinib
#1
LETTER
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, Alessandra Iurlo, Nicola Polverelli, Elena Elli, Massimiliano Bonifacio, Micaela Bergamaschi, Bruno Martino, Mario Tiribelli, Giulia Benevolo, Alessia Tieghi, Nicola Sgherza, Alessandro Isidori, Gianni Binotto, Monica Crugnola, Florian Heidel, Francesco Cavazzini, Costanza Bosi, Giuseppe Auteri, Daniele Cattaneo, Robin Foà, Roberto M Lemoli, Antonio Cuneo, Mauro Krampera, Daniela Bartoletti, Michele Cavo, Nicola Vianelli, Massimo Breccia, Roberto Latagliata
2016-WHO criteria identified early-Primary Myelofibrosis as an individual entity with milder clinical features and better outcome compared to overt-PMF. Here, we compared early and overt-PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of haematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts...
April 15, 2019: Hematological Oncology
https://read.qxmd.com/read/30983008/a-multi-center-retrospective-comparison-of-induction-chemoimmunotherapy-regimens-on-outcomes-in-transplant-eligible-patients-with-previously-untreated-mantle-cell-lymphoma
#2
Zi Yun Ng, Mark Bishton, David Ritchie, Robert Campbell, Michael Gilbertson, Kate Hill, Sumita Ratnasingam, Anthony Schwarer, Kate Manos, Sophie Shorten, Melissa Ng, Niles Nelson, Liu Xin, Sanjay De Mel Widanalage, Tenny Sunny, Duncan Purtill, Michelle Poon, Anna Johnston, Tara Cochrane, Hui-Peng Lee, Greg Hapgood, Constantine Tam, Stephen Opat, Eliza Hawkes, John Seymour, Chan Yoon Cheah
Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant eligible patients and the optimal approach remains unknown. We performed an international, retrospective study of transplant eligible patients to assess impact of induction chemo-immunotherapy and conditioning regimens on clinical outcomes. We identified 228 patients meeting inclusion criteria. Baseline characteristics were similar among the induction groups except for some variation in age...
April 15, 2019: Hematological Oncology
https://read.qxmd.com/read/30950076/smoking-influences-the-outcomes-of-patients-receiving-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia-in-the-chronic-phase-a-retrospective-analysis
#3
LETTER
Noriyoshi Iriyama, Michihide Tokuhira, Eriko Sato, Kei-Ji Sugimoto, Tomoiku Takaku, Maho Ishikawa, Tomonori Nakazato, Hiroyuki Fujita, Yuta Kimura, Isao Fujioka, Norio Asou, Norio Komatsu, Masahiro Kizaki, Yoshihiro Hatta, Tatsuya Kawaguchi
No abstract text is available yet for this article.
April 4, 2019: Hematological Oncology
https://read.qxmd.com/read/30945323/identification-of-a-novel-trna-derived-rna-fragment-exhibiting-high-prognostic-potential-in-chronic-lymphocytic-leukemia
#4
Paraskevi Karousi, Katerina Katsaraki, Sotirios G Papageorgiou, Vasiliki Pappa, Andreas Scorilas, Christos K Kontos
tRNA-derived fragments (tRFs) are 16-28 nucleotide fragments, which occur by specific cleavage of tRNA molecules. i-tRF-GlyGCC is an internal tRF, originating from the tRNAs bearing the Glycine anticodon "GCC". Other tRFs generated from tRNAGlyGCC have proved to be associated with various cancer types. Chronic lymphocytic leukemia (CLL) is a type of leukemia during which CD5+ B lymphocytes accumulate in marrow and lymphoid tissues and is characterized by differential clinical features among patients...
April 4, 2019: Hematological Oncology
https://read.qxmd.com/read/30938858/induction-therapy-in-acute-myeloid-leukemia-is-it-time-to-put-aside-standard-3-7
#5
REVIEW
Felicetto Ferrara, Orsola Vitagliano
For more than 30 years after its introduction, the combination of an anthracycline, usually daunorubicin, given for 3 days with continuous infusion of cytarabine for 7 days (3+7) has been the standard induction regimen for patients with acute myeloid leukemia (AML). In the last decade, there has been a progressive understanding of the molecular pathogenesis of the disease which has led to discovery of potential therapeutic targets, resulting in selective treatment approaches aimed at rational and personalized treatment strategies...
April 2, 2019: Hematological Oncology
https://read.qxmd.com/read/30938848/front-line-treatment-of-diffuse-large-b-cell-lymphoma-beyond-r-chop
#6
REVIEW
Patrizia Mondello, Michael Mian
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies...
April 2, 2019: Hematological Oncology
https://read.qxmd.com/read/30938836/patients-assigned-to-vgpr-pr-and-sd-in-the-imwg-response-category-are-composed-of-heterogeneous-population-when-assessed-by-the-heavy-light-chain-assay
#7
LETTER
Yoshikazu Kamiya, Takaaki Chou, Hirokazu Murakami, Hiroshi Handa, Shuji Ozaki, Chihiro Shimazaki, Shin-Ichi Fuchida, Jun Okada, Junji Itoh, Satoru Sugiyama, Kazuyuki Shimizu
No abstract text is available yet for this article.
April 2, 2019: Hematological Oncology
https://read.qxmd.com/read/30933368/metabolic-tumour-volume-and-response-to-therapy-in-diffuse-large-b-cell-lymphoma
#8
LETTER
Leonardo Campiotti, Matteo B Suter, Diego De Palma, Ilaria Proserpio, Silvia Uccella, Alessandro Squizzato
No abstract text is available yet for this article.
April 1, 2019: Hematological Oncology
https://read.qxmd.com/read/30933366/relative-dose-intensity-of-r-chop-therapy-and-patient-outcomes-in-advanced-follicular-lymphoma
#9
LETTER
Tatsuya Konishi, Yusuke Kanemasa, Yuki Sasaki, Toshihiro Okuya, Tsukasa Yamaguchi, Chikako Funasaka, Tatsu Shimoyama, Yasushi Omuro
No abstract text is available yet for this article.
April 1, 2019: Hematological Oncology
https://read.qxmd.com/read/30924173/rna-seq-analyses-demonstrate-evi-1-induced-morbid-hematopoiesis-and-developmental-abnormality-in-zebrafish-were-related-with-mapk-pathway
#10
LETTER
Wenjing Lang, Jiayi Cai, Fangyuan Chen, Jianyi Zhu, Xiaoli Hu, Jihua Zhong
No abstract text is available yet for this article.
March 28, 2019: Hematological Oncology
https://read.qxmd.com/read/30920666/dysregulation-of-interferon-regulatory-genes-reinforces-the-concept-of-chronic-immune-response-in-myelodysplastic-syndrome-pathogenesis
#11
LETTER
Juliana Cordeiro de Sousa, Mayumi da Nóbrega Ito, Marilia Braga Costa, Izabelle Rocha Farias, Daniela de Paula Borges, Roberta Taiane de Oliveira, Kiyoshi Ferreira Fukutani, Carolina Hassibe Thomé, Camila Maria da Silva Martinelli, Fabio Myajima, Daniel Onofre Vidal, Silvia Maria Meira Magalhães, Lorena Lobo Figueiredo-Pontes, Ronald Feitosa Pinheiro
No abstract text is available yet for this article.
March 28, 2019: Hematological Oncology
https://read.qxmd.com/read/30916804/cardiovascular-mortality-among-patients-with-non-hodgkin-lymphoma-differences-according-to-lymphoma-subtype
#12
Hasan Abuamsha, Amer N Kadri, Adrian V Hernandez
Survival rates of patients with non-Hodgkin lymphoma (NHL) have improved over the last decade. However, cardiotoxicities remain important adverse consequences of treatment with chemotherapy and radiation, although the burden of cardiovascular mortality (CVM) in such patients remains unknown. We conducted a retrospective cohort study of patients ≥20 years of age diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) between 2000 and 2013 using data extracted from the United States Surveillance, Epidemiology, and End Results (SEER) database...
March 27, 2019: Hematological Oncology
https://read.qxmd.com/read/30892724/arterial-occlusive-events-in-chronic-myeloid-leukemia-patients-treated-with-ponatinib-in-the-real-life-practice-are-predicted-by-the-systematic-coronary-risk-evaluation-score-chart
#13
Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese, Luigiana Luciano, Alessandra Iurlo, Immacolata Attolico, Fausto Castagnetti, Sara Galimberti, Nicola Sgherza, Massimiliano Bonifacio, Mario Annunziata, Antonella Gozzini, Ester Maria Orlandi, Fabio Stagno, Gianni Binotto, Patrizia Pregno, Claudio Fozza, Malgorzata Monika Trawinska, Fiorenza De Gregorio, Daniele Cattaneo, Francesco Albano, Gabriele Gugliotta, Claudia Baratè, Luigi Scaffidi, Chiara Elena, Francesca Pirillo, Emilia Scalzulli, Giorgio La Nasa, Robin Foà, Massimo Breccia
Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML adult patients who were treated with ponatinib in 17 Italian centers. Patients were stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 60-month cumulative incidence rate of AOEs excluding hypertension was 25.7%. Hypertension was reported in 14...
March 20, 2019: Hematological Oncology
https://read.qxmd.com/read/30849188/a-case-report-of-systemic-mastocytosis-associated-with-multiple-hematologic-non-mast-cell-lineage-diseases
#14
Federica Irene Grifoni, Mariarita Sciumé, Valerio Pravettoni, Fabio Massimo Ulivieri, Simona Muratori, Nicola Stefano Fracchiolla, Elena Tagliaferri, Umberto Gianelli, Anna Chiara Migliorini, Lilla Cro, Annalisa Pacilli, Francesco Mannelli, Luca Baldini
Systemic mastocytosis is a hematological malignancy characterized by extracutaneous infiltration by atypical mast cells. Together with indolent systemic mastocytosis, aggressive systemic mastocytosis and mast cell leukemia, the World Health Organization (WHO) recognizes another major disease subgroup: systemic mastocytosis with an associated hematological neoplasm which is characterized by presence of a concurrent neoplasm, more commonly a chronic myelomonocytic leukemia. While KIT D816V is commonly regarded as the driver mutation, the clinical presentation of SM is extremely varied...
March 8, 2019: Hematological Oncology
https://read.qxmd.com/read/30847943/reassessment-of-risk-factors-and-long-term-results-of-autologous-stem-cell-transplantation-in-relapsed-and-refractory-classical-hodgkin-lymphoma
#15
LETTER
Giancarlo Fatobene, Camila da Cruz Gouveia Linardi, Frederico Moreira, Gabriela Matos Falcão Targueta, Fernanda Maria Santos, Rodrigo Dolphini Velasques, Vanderson Rocha, Valeria Buccheri
No abstract text is available yet for this article.
March 7, 2019: Hematological Oncology
https://read.qxmd.com/read/30843248/critical-evaluation-of-current-molecular-mrd-strategies-including-ngs-for-the-management-of-aml-patients-with-multiple-mutations
#16
LETTER
Evgenii Shumilov, Johanna Flach, Raphael Joncourt, Naomi Porret, Gertrud Wiedemann, Anne Angelillo-Scherrer, Lorenz Trümper, Martin Fiedler, Barbara Jeker, Ursula Amstutz, Thomas Pabst, Ulrike Bacher
No abstract text is available yet for this article.
March 6, 2019: Hematological Oncology
https://read.qxmd.com/read/30840776/transformed-follicular-lymphoma-in-the-rituximab-era-a-report-from-the-spanish-lymphoma-oncology-group
#17
M Méndez, M Torrente, M Sánchez-Beato, J González-Rincón, A Royuela, J Gómez-Codina, L de la Cruz-Merino, A Rueda, M Llanos, C Quero, D Rodríguez-Abreu, J Gumá, S Monsalvo, P Sabin, M Provencio
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) subtype. The histological transformation (HT) of FL is an event considered frequent in the natural history of this tumor. We studied the transformation rates, predictive factors and treatment characteristics that may impact in the survival of patients with FL and HT. A total of 1074 patients diagnosed with FL were prospectively enrolled from 1990 to 2016 in a Spanish registry. 64 HTs were recorded based on clinical criteria (55%) or histological confirmation (45%)...
March 6, 2019: Hematological Oncology
https://read.qxmd.com/read/30835862/the-italian-canine-cancer-icc-biobank-our-10-year-challenge
#18
LETTER
L Aresu, P Buracco, R De Maria, S Iussich, M Martano, E Morello, G Bettini, S Comazzi, F Riondato, L Marconato
No abstract text is available yet for this article.
March 5, 2019: Hematological Oncology
https://read.qxmd.com/read/30821017/dual-tracer-pet-ct-scan-after-injection-of-combined-18f-naf-and-18f-fdg-outperforms-mri-in-the-detection-of-myeloma-lesions
#19
Nadia Withofs, Yves Beguin, François Cousin, Tino Tancredi, Paolo Simoni, Victoria Alvarez-Miezentseva, Bernard De Prijck, Kaoutar Hafraoui, Christophe Bonnet, Frédéric Baron, Roland Hustinx, Jo Caers
The detection rates of whole-body combined [18F]NaF/[18F]FDG PET/CT, CT alone, MRI and X-ray were prospectively studied in patients with treatment-requiring plasma cell disorders The detection rates of imaging techniques were compared and focal lesions were classified according to their anatomic location. Twenty-six out of 30 initially included patients were assessable. The number of focal lesions detected in newly diagnosed patients (n = 13) and in relapsed patients (n = 13) were 296 and 234, respectively...
February 28, 2019: Hematological Oncology
https://read.qxmd.com/read/30756414/low-dose-fludarabine-and-cyclophosphamide-combined-with-standard-dose-rituximab-ld-fcr-is-an-effective-and-safe-regimen-for-elderly-untreated-patients-with-chronic-lymphocytic-leukemia-the-israeli-cll-study-group-experience
#20
Yair Herishanu, Tamar Tadmor, Andrei Braester, Osnat Bairey, Ariel Aviv, Naomi Rahimi-Levene, Riva Fineman, Itai Levi, Mona Yuklea, Rosa Ruchlemer, Lev Shvidel, Aaron Polliack
Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL, however, this combination is toxic for older patients. At the time this study was first planned and initiated, there was no standard chemo-immunotherapy regimen regarded as standard therapy for the less fit elderly patient with CLL. Here we conducted a single arm, phase II trial to examine the efficacy and safety of lower-dose fludarabine and cyclophosphamide combined with a standard dose of rituximab (LD-FCR) in elderly patients with previously untreated CLL...
February 12, 2019: Hematological Oncology
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"